Pancreatic Cancer Research

ResearcherMedical College of WisconsinActive in the last 2 years

Susan Tsai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3685-2451; OpenAlex author ID A5041591287. Sources: ClinicalTrials.gov.

Their work

Papers
86 (first author 10, last author 27)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
194
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 7 papers · 2015: 8 papers · 2016: 7 papers · 2017: 4 papers, 1 trial · 2018: 4 papers · 2019: 6 papers · 2020: 9 papers · 2021: 11 papers · 2022: 6 papers · 2023: 8 papers · 2024: 5 papers · 2025: 2 papers · 2026: 7 papers

Papers 50 of 86

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  2. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  3. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
  4. The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer. First author DOI 10.1245/s10434-026-20366-0↗
  5. ASO Visual Abstract: The Landmark Series-Mutation-Based Therapy of Pancreatic Cancer. First author DOI 10.1245/s10434-026-20458-x↗
  6. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.21203/rs.3.rs-8545050/v1↗
  7. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.64898/2026.01.06.26343539↗
  8. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  9. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03167-2↗
  10. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  11. Use of Diagnostic Laparoscopy and Peritoneal Washings for Pancreatic Cancer. First author DOI 10.1016/j.suc.2024.05.004↗
  12. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2024.01.028↗
  13. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Co-author DOI 10.1177/17588359241253113↗
  14. Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival. Co-author DOI 10.3748/wjg.v30.i7.714↗
  15. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. Last author DOI 10.1001/jamaoncol.2022.6138↗
  16. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Last author DOI 10.1002/jso.27265↗
  17. Impact of Medicaid Expansion on Stage at Diagnosis for US Adults with Pancreatic Cancer: a Population-Based Study. Co-author DOI 10.1007/s40615-022-01459-4↗
  18. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Co-author DOI 10.1016/j.adro.2022.101122↗
  19. Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2023.09.008↗
  20. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000005884↗
  21. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Res… Co-author DOI 10.1245/s10434-022-12742-3↗
  22. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Last author DOI 10.1245/s10434-022-13055-1↗
  23. Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer. Co-author DOI 10.1002/jso.26756↗
  24. Undifferentiated carcinoma with osteoclast-like giant cells: A pathologic-radiologic correlation of a rare histologic subtype of pancreatic ductal adenocarcino… Co-author DOI 10.1016/j.anndiagpath.2021.151884↗
  25. Novel Considerations in Surgical Management of Individuals with Pancreatic Adenocarcinoma. First author DOI 10.1016/j.hoc.2022.07.004↗
  26. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003945↗
  27. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  28. CXCR4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer. First author DOI 10.1371/journal.pone.0264763↗
  29. Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. Last author DOI 10.1002/jso.26395↗
  30. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Co-author DOI 10.1007/s10555-021-09993-z↗
  31. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Last author DOI 10.1016/j.amjsurg.2020.12.001↗
  32. Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. Last author DOI 10.1016/j.soc.2021.06.010↗
  33. Updates on the Management of Pancreatic Cancer. Co-author DOI 10.1016/j.soc.2021.07.001↗
  34. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.06.038↗
  35. Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes. Co-author DOI 10.1038/s41698-021-00161-8↗
  36. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Co-author DOI 10.1158/1078-0432.ccr-20-2475↗
  37. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  38. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Last author DOI 10.1245/s10434-020-09149-3↗
  39. Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. Co-author DOI 10.3389/fonc.2021.606820↗
  40. Black raspberries suppress pancreatic cancer through modulation of NKp46+, CD8+, and CD11b+ immune cells. Co-author DOI 10.1002/fft2.1↗
  41. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? Last author DOI 10.1007/s11605-019-04423-6↗
  42. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.anndiagpath.2020.151485↗
  43. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Last author DOI 10.1016/j.hpb.2020.03.022↗
  44. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Last author DOI 10.1016/j.surg.2020.04.031↗
  45. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
  46. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Last author DOI 10.3389/fonc.2020.00460↗
  47. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Last author DOI 10.3389/fonc.2020.00500↗
  48. Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment Co-author DOI 10.3389/fonc.2020.00553↗
  49. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  50. Has Personalized Medicine for Pancreatic Cancer Arrived? First author DOI 10.1016/j.yasu.2019.04.006↗

Trials 1

  1. Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer Principal investigator NCT02775695↗

Closest collaborators

The 25 strongest of 194 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Douglas B. Evans · 61 shared papers, 2012–2026 · strength 6.86
  2. Kathleen K. Christians · 38 shared papers, 2013–2026 · strength 3.68
  3. William Adrian Hall · 27 shared papers, 2017–2026 · strength 3.64
  4. Mohammed Aldakkak · 28 shared papers, 2015–2026 · strength 3.51
  5. Bradley A. Erickson · 33 shared papers, 2014–2024 · strength 3.11
  6. Ben George · 30 shared papers, 2014–2024 · strength 2.80
  7. Mandana Kamgar · 16 shared papers, 2019–2026 · strength 2.58
  8. Callisia Nathelee Clarke · 14 shared papers, 2017–2025 · strength 1.77
  9. Kulwinder S. Dua · 10 shared papers, 2016–2025 · strength 1.16
  10. Ashley N. Krepline · 12 shared papers, 2014–2021 · strength 1.08
  11. McKenzie L. Schaefer · 2 shared papers, 2026 · strength 1.00
  12. Alex B. Blair · 2 shared papers, 2026 · strength 1.00
  13. Parag P. Tolat · 14 shared papers, 2012–2023 · strength 0.99
  14. Chad A. Barnes · 7 shared papers, 2017–2022 · strength 0.86
  15. Beth E. Erickson · 5 shared papers, 2019–2026 · strength 0.80
  16. Thomas B. McFall · 4 shared papers, 2024–2026 · strength 0.74
  17. Razelle Kurzrock · 4 shared papers, 2024–2026 · strength 0.74
  18. Sam Z. Thalji · 4 shared papers, 2023–2026 · strength 0.69
  19. Naveen M. Kulkarni · 6 shared papers, 2018–2023 · strength 0.68
  20. Erin P. Ward · 3 shared papers, 2021–2022 · strength 0.63
  21. Daniel D. Von Hoff · 4 shared papers, 2022–2025 · strength 0.61
  22. Ben George · 3 shared papers, 2024–2026 · strength 0.59
  23. Nikki K. Lytle · 3 shared papers, 2023–2026 · strength 0.55
  24. Upender Manne · 2 shared papers, 2026 · strength 0.53
  25. Ashwini Kumar Esnakula · 2 shared papers, 2026 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.